Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Recurrence × 3-Iodobenzylguanidine × Clear all

Status

Completed 2 Available 2 Unknown 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Pheochromocytoma 2 Paraganglioma 2 Recurrence 1 Neuroblastoma 1 Neoplasms 1

Interventions

ibrutinib 2 vorasidenib 1 talquetamab 1 pomalidomide 1 fludarabine 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 Cyclophosphamide 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡